Alois Alzheimer first described his eponymous disease a century ago, but there are still no effective treatments. For World Alzheimer’s Day, Professor Bart de Strooper, Director of the UK Dementia Research Institute, asks why that is, and tells us how that might all be about to change.
Professor Bart de Strooper
In the early 1900s, a German neurologist called Alois Alzheimer became obsessed with studying an Asylum patient in her 50s, who had started to show unusual behavioural changes, including short-term memory loss. After her death he examined her brain and discovered structures known as amyloid plaques and neurofibrillary tangles – the hallmarks of what became known as Alzheimer’s disease. So why, when we’ve known about the disease for so long, are there still no treatments? Read more
Research published today, funded by the MRC* and the Alzheimer’s Society’s Drug Discovery programme, has made important progress in the search for new treatments for dementia by re-purposing old drugs. Dr Louise Walker, Research Communications Officer at the Alzheimer’s Society, spoke to the scientist who led the research, Professor Giovanna Mallucci at the MRC Toxicology Unit, to find out more.
Alzheimer’s disease and other degenerative brain diseases are characterised by the presence of misfolded proteins in the brain. These proteins are thought to have toxic effects on brain cells, but exactly how they contribute to dementia still remains a mystery.
Jennifer Lawson is the Trials Manager for the recently launched Deep and Frequent Phenotyping study looking to do the most in-depth research ever conducted to find out how Alzheimer’s disease develops. She is part of Professor Simon Lovestone’s Translational Neuroscience and Dementia Research group at the University of Oxford.
Career in brief
- Psychology BSc
- Worked at the Oxford Mental Health Trust as a Research Coordinator
- Part time Cognitive Neuroscience MSc whilst working full time at the Trust
- Managed the feasibility study that has led to this Deep and Frequent Phenotyping study
My career path has been slightly unusual. Like many of my peers studying psychology, I planned to become a clinical psychologist. So I went to gain experience working in Oxford Health NHS Foundation Trust, assisting with clinical trials and other research studies.